Posted by Michael Wonder on 18 May 2026
Qalsody: new data has allowed for a reassessment by the HAS
21 April 2026 - The drug Qalsody (tofersen) aims to slow the progression of a rare genetic form of ALS (amyotrophic lateral sclerosis) caused by a mutation in the SOD1 gene.
This treatment, which has raised high hopes among patients and their families, has been reassessed by the Transparency Committee of the French National Authority for Health.
Based on new data, the Committee has issued a statement recognising a limited but conditional medical benefit for Qalsody.
